

Amendments to the Claims:

1-60. (Canceled)

61. (Currently amended) A method for inducing an immune response to a flaviviral antigen in a human subject comprising delivering a vaccine expressing the flaviviral antigen to a subject's skin using a device that targets the intradermal compartment of the subject's skin, wherein the device comprises at least one hollow microneedle that delivers the vaccine to the subject's skin to a depth of between 0.025 mm and 2.0 mm.

62-63. (Canceled)

64. (Currently amended) A kit for use in inducing an immune response to a flaviviral antigen in a subject, said kit comprising:

(a) a vaccine expressing the flaviviral antigen; and

(b) a device that targets the intradermal compartment of the subject's skin, wherein the device comprises:

(1) at least one microneedle, wherein the microneedle is supported by a hub portion and has a forward tip that extends away from the hub portion; and

(2) a limiter portion that surrounds the microneedle and extends away from the hub portion toward the forward tip of the microneedle, wherein the limiter portion comprises a flat skin engaging surface that extends in a plane perpendicular to an axis of the microneedle, the forward tip of the microneedle extending beyond the skin engaging surface at a distance of between 0.5 mm and 2.0 mm.

65. (Canceled)

66. (Previously presented) The method of claim 61, wherein the vaccine is a chimeric Japanese Encephalitis vaccine.

Appl. No.: 10/679,038
Amdt. dated February 27, 2008
Reply to Office Action of November 27, 2007

67. (Previously presented) The method of claim 66, wherein the chimeric Japanese Encephalitis vaccine is JE SA14-14-2.

68. (Previously presented) The kit of claim 64, wherein the vaccine is a chimeric Japanese Encephalitis vaccine.

69. (Currently amended) The kit of claim 68 ~~65~~, wherein the chimeric Japanese Encephalitis vaccine is JE SA14-14-2.